Skip to main content
Top

Breast Cancer Research and Treatment

Issue 1/2016

Content (20 Articles)

Open Access Preclinical study

Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies

Akira I. Hida, Yasuaki Sagara, Daisuke Yotsumoto, Shuichi Kanemitsu, Junko Kawano, Shinichi Baba, Yoshiaki Rai, Yumi Oshiro, Kenjiro Aogi, Yoshiaki Sagara, Yasuyo Ohi

Preclinical study

Proliferation assessment in breast carcinomas using digital image analysis based on virtual Ki67/cytokeratin double staining

Rasmus Røge, Rikke Riber-Hansen, Søren Nielsen, Mogens Vyberg

Preclinical study

Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression

Yanhong Zhang, Adam L. Liss, Eugene Chung, Lori J. Pierce, Celina G. Kleer

Preclinical study

Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention

Justin A. Colacino, Sean P. McDermott, Maureen A. Sartor, Max S. Wicha, Laura S. Rozek

Preclinical study

Aberrant nocturnal cortisol and disease progression in women with breast cancer

Jamie M. Zeitzer, Bita Nouriani, Michelle B. Rissling, George W. Sledge, Katherine A. Kaplan, Linn Aasly, Oxana Palesh, Booil Jo, Eric Neri, Firdaus S. Dhabhar, David Spiegel

Clinical trial

Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients

Alexander Hein, Paul Gass, Christina Barbara Walter, Florin-Andrei Taran, Andreas Hartkopf, Friedrich Overkamp, Hans-Christian Kolberg, Peyman Hadji, Hans Tesch, Johannes Ettl, Rachel Wuerstlein, Debra Lounsbury, Michael P. Lux, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Erik Belleville, Wolfgang Janni, Tanja N. Fehm, Diethelm Wallwiener, Thomas Ganslandt, Matthias Ruebner, Matthias W. Beckmann, Andreas Schneeweiss, Peter A. Fasching, Sara Y. Brucker

Clinical trial

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer

Banu K. Arun, Yun Gong, Diane Liu, Jennifer K. Litton, Angelica M. Gutierrez-Barrera, J. Jack Lee, Lana Vornik, Nuhad K. Ibrahim, Terri Cornelison, Gabriel N. Hortobagyi, Brandy M. Heckman-Stoddard, Kimberly B. Koenig, Ricardo R. Alvarez, James L. Murray, Vicente Valero, Scott M. Lippman, Powel Brown, Nour Sneige

Clinical Trial

Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study

L. M. Smyth, N. M. Iyengar, M. F. Chen, S. M. Popper, S. Patil, C. Wasserheit-Lieblich, D. F. Argolo, J. C. Singh, S. Chandarlapaty, S. M. Sugarman, E. A. Comen, P. R. Drullinsky, T. A. Traina, T. Troso-Sandoval, J. Baselga, L. Norton, C. A. Hudis, C. T. Dang

Open Access Clinical trial

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

Sasagu Kurozumi, Mary Padilla, Masafumi Kurosumi, Hiroshi Matsumoto, Kenichi Inoue, Jun Horiguchi, Izumi Takeyoshi, Tetsunari Oyama, Jim Ranger-Moore, D. Craig Allred, Eslie Dennis, Hiroaki Nitta

Epidemiology

Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians

Tulay Koru-Sengul, Ana M. Santander, Feng Miao, Lidia G. Sanchez, Merce Jorda, Stefan Glück, Tan A. Ince, Mehrad Nadji, Zhibin Chen, Manuel L Penichet, Margot P. Cleary, Marta Torroella-Kouri

Epidemiology

A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL)

Alfred I. Neugut, Grace Clarke Hillyer, Lawrence H. Kushi, Lois Lamerato, Donna L. Buono, S. David Nathanson, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Wei-Yann Tsai, Judith S. Jacobson, Dawn L. Hershman

Epidemiology

Preoperative breast magnetic resonance imaging and contralateral breast cancer occurrence among older women with ductal carcinoma in situ

Shi-Yi Wang, Jessica B. Long, Brigid K. Killelea, Suzanne B. Evans, Kenneth B. Roberts, Andrea Silber, Cary P. Gross

Epidemiology

Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses’ Health Study and Nurses’ Health Study II

Kelly A. Hirko, Renée T. Fortner, Susan E. Hankinson, Tianying Wu, A. Heather Eliassen

Epidemiology

Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women

Lital Keinan-Boker, Hagai Levine, Estela Derazne, Vered Molina-Hazan, Jeremy D. Kark

Open Access Epidemiology

The recurrence pattern following delayed breast reconstruction after mastectomy for breast cancer suggests a systemic effect of surgery on occult dormant micrometastases

Hanna Dillekås, Romano Demicheli, Ilaria Ardoino, Svein A. H. Jensen, Elia Biganzoli, Oddbjørn Straume

Open Access Epidemiology

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

Shusma C. Doebar, Esther C. van den Broek, Linetta B. Koppert, Agnes Jager, Margreet. H. A. Baaijens, Inge-Marie A. M. Obdeijn, Carolien H. M. van Deurzen

Brief Report

Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer

Shruti R. Tiwari, Prasun Mishra, Paola Raska, Benjamin Calhoun, Jame Abraham, Halle Moore, G. Thomas Budd, Alicia Fanning, Stephanie Valente, Robyn Stewart, Stephen R. Grobmyer, Alberto J. Montero

Brief Report

Genomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lung

Brennan McCullar, Manjari Pandey, George Yaghmour, Felicia Hare, Kruti Patel, Matthew Stein, Rebecca Feldman, Jason C. Chandler, Michael G. Martin

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine